S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
Log in

Innovus Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:INNV)

$2.10
-0.09 (-4.11 %)
(As of 10/17/2019 04:00 PM ET)
Today's Range
$1.86
Now: $2.10
$2.10
50-Day Range
$1.33
MA: $1.94
$2.75
52-Week Range
$1.05
Now: $2.10
$12.59
Volume3,662 shs
Average Volume7,117 shs
Market Capitalization$5.49 million
P/E RatioN/A
Dividend YieldN/A
Beta2.26
Innovus Pharmaceuticals, Inc, a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:INNV
Previous SymbolNASDAQ:INNV
CUSIPN/A
Phone858-964-5123

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.99 million
Book Value$0.05 per share

Profitability

Net Income$-8,280,000.00

Miscellaneous

Employees27
Market Cap$5.49 million
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable

Receive INNV News and Ratings via Email

Sign-up to receive the latest news and ratings for INNV and its competitors with MarketBeat's FREE daily newsletter.


Innovus Pharmaceuticals (OTCMKTS:INNV) Frequently Asked Questions

What is Innovus Pharmaceuticals' stock symbol?

Innovus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "INNV."

How were Innovus Pharmaceuticals' earnings last quarter?

Innovus Pharmaceuticals Inc (OTCMKTS:INNV) announced its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.47. The business had revenue of $6.85 million for the quarter, compared to analysts' expectations of $7.65 million. Innovus Pharmaceuticals had a negative return on equity of 1,618.20% and a negative net margin of 34.33%. View Innovus Pharmaceuticals' Earnings History.

When is Innovus Pharmaceuticals' next earnings date?

Innovus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Innovus Pharmaceuticals.

What price target have analysts set for INNV?

1 brokerages have issued 1-year price objectives for Innovus Pharmaceuticals' stock. Their predictions range from $5.00 to $5.00. On average, they anticipate Innovus Pharmaceuticals' stock price to reach $5.00 in the next year. This suggests a possible upside of 138.1% from the stock's current price. View Analyst Price Targets for Innovus Pharmaceuticals.

What is the consensus analysts' recommendation for Innovus Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innovus Pharmaceuticals.

Has Innovus Pharmaceuticals been receiving favorable news coverage?

News coverage about INNV stock has been trending somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Innovus Pharmaceuticals earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Innovus Pharmaceuticals.

Who are some of Innovus Pharmaceuticals' key competitors?

What other stocks do shareholders of Innovus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovus Pharmaceuticals investors own include EEStor (ESU), Antares Pharma (ATRS), The Medicines (MDCO), Federal National Mortgage Association (FNMA), Frontier Communications (FTR), Republic First Bancorp (FRBK), FedEx (FDX), NVIDIA (NVDA), OvaScience (OVAS) and Pacific Premier Bancorp (PPBI).

Who are Innovus Pharmaceuticals' key executives?

Innovus Pharmaceuticals' management team includes the folowing people:
  • Dr. Bassam B. Damaj, Pres, CEO & Director (Age 51)
  • Mr. Ryan J. Selhorn CPA, VP & CFO (Age 37)
  • Mr. Randy J. Berholtz, Exec. VP of Corp. Devel., Gen. Counsel & Sec. (Age 58)
  • Mr. Christopher Stella, VP of Operations
  • Mr. Robert C. Verfurth, VP of Sales & Marketing

How do I buy shares of Innovus Pharmaceuticals?

Shares of INNV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Innovus Pharmaceuticals' stock price today?

One share of INNV stock can currently be purchased for approximately $2.10.

How big of a company is Innovus Pharmaceuticals?

Innovus Pharmaceuticals has a market capitalization of $5.49 million and generates $23.99 million in revenue each year. The company earns $-8,280,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. Innovus Pharmaceuticals employs 27 workers across the globe.View Additional Information About Innovus Pharmaceuticals.

What is Innovus Pharmaceuticals' official website?

The official website for Innovus Pharmaceuticals is http://www.innovuspharma.com/.

How can I contact Innovus Pharmaceuticals?

Innovus Pharmaceuticals' mailing address is 8845 Rehco Road, San Diego CA, 92121. The company can be reached via phone at 858-964-5123 or via email at [email protected]


MarketBeat Community Rating for Innovus Pharmaceuticals (OTCMKTS INNV)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  233
MarketBeat's community ratings are surveys of what our community members think about Innovus Pharmaceuticals and other stocks. Vote "Outperform" if you believe INNV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INNV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel